# Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants

> **NCT05751642** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **BIOLOGICAL:** ALXN1920
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** ALXN1920
- **BIOLOGICAL:** ALXN1920

## Key facts

- **NCT ID:** NCT05751642
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-19
- **Primary completion:** 2023-12-04
- **Final completion:** 2023-12-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751642, "Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05751642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*